Advertisement
Advertisement
U.S. markets open in 1 hour 50 minutes
Advertisement
Advertisement
Advertisement
Advertisement

(AMGN34.SA)

. Currency in USD
- (-)
Advertisement
  • Dividend

    AMGN34.SA announced a cash dividend of 0.401 with an ex-date of Feb. 14, 2023

Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close45.55
Open0.00
BidN/A x N/A
AskN/A x N/A
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. VolumeN/A
Market Cap658.614B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)2.28
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for AMGN34.SA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Motley Fool

      Why Amgen Stock Wilted on Wednesday

      The stock of veteran biotech Amgen (NASDAQ: AMGN) was looking a little tired on Wednesday. The company's shares fell more than 2% in price, "thanks" to fourth-quarter results that didn't put smiles on investors' faces. In contrast to gloomy Amgen, the S&P 500 index ticked up by slightly more than 1%.

    • Investor's Business Daily

      There's A Key Element Missing From Amgen's 2023 Outlook, Making Comparisons 'Messy'

      Amgen issued an outlook that discounts its looming acquisition of Horizon Therapeutics. In response, Amgen stock skidded Wednesday morning.

    • Reuters

      FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high

      U.S. patients will finally get access to cheaper versions of AbbVie Inc’s blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. Rival drugmaker Amgen Inc on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20-year-old drug, with two tiers of pricing. One sets a 5% discount to Humira’s monthly price of $6,922.

    Advertisement
    Advertisement